These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 30962949)

  • 1. Glucocorticoid-resistant B cell acute lymphoblastic leukemia displays receptor tyrosine kinase activation.
    Chougule RA; Shah K; Moharram SA; Vallon-Christersson J; Kazi JU
    NPJ Genom Med; 2019; 4():7. PubMed ID: 30962949
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.
    von Bubnoff N; Engh RA; Aberg E; Sänger J; Peschel C; Duyster J
    Cancer Res; 2009 Apr; 69(7):3032-41. PubMed ID: 19318574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant activation of the PI3K/mTOR pathway promotes resistance to sorafenib in AML.
    Lindblad O; Cordero E; Puissant A; Macaulay L; Ramos A; Kabir NN; Sun J; Vallon-Christersson J; Haraldsson K; Hemann MT; Borg Å; Levander F; Stegmaier K; Pietras K; Rönnstrand L; Kazi JU
    Oncogene; 2016 Sep; 35(39):5119-31. PubMed ID: 26999641
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
    Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
    J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LAM-003, a new drug for treatment of tyrosine kinase inhibitor-resistant FLT3-ITD-positive AML.
    Beeharry N; Landrette S; Gayle S; Hernandez M; Grotzke JE; Young PR; Beckett P; Zhang X; Carter BZ; Andreeff M; Halene S; Xu T; Rothberg J; Lichenstein H
    Blood Adv; 2019 Nov; 3(22):3661-3673. PubMed ID: 31751472
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Flt3 receptor tyrosine kinase as a drug target in leukemia.
    Schmidt-Arras D; Schwäble J; Böhmer FD; Serve H
    Curr Pharm Des; 2004; 10(16):1867-83. PubMed ID: 15180525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanisms of resistance against PKC412 in resistant FLT3-ITD positive human acute myeloid leukemia cells.
    Stölzel F; Steudel C; Oelschlägel U; Mohr B; Koch S; Ehninger G; Thiede C
    Ann Hematol; 2010 Jul; 89(7):653-62. PubMed ID: 20119833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of foetal-like tyrosine kinase 3 mutation in Egyptian children with acute leukaemia.
    Al-Tonbary Y; Mansour AK; Ghazy H; Elghannam DM; Abd-Elghaffar HA
    Int J Lab Hematol; 2009 Jun; 31(3):320-6. PubMed ID: 18336585
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.
    Nakao M; Yokota S; Iwai T; Kaneko H; Horiike S; Kashima K; Sonoda Y; Fujimoto T; Misawa S
    Leukemia; 1996 Dec; 10(12):1911-8. PubMed ID: 8946930
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children.
    Xu F; Taki T; Yang HW; Hanada R; Hongo T; Ohnishi H; Kobayashi M; Bessho F; Yanagisawa M; Hayashi Y
    Br J Haematol; 1999 Apr; 105(1):155-62. PubMed ID: 10233379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors.
    Nguyen B; Williams AB; Young DJ; Ma H; Li L; Levis M; Brown P; Small D
    Oncotarget; 2017 Feb; 8(7):10931-10944. PubMed ID: 28077790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resistance to FLT3 inhibitors in acute myeloid leukemia: Molecular mechanisms and resensitizing strategies.
    Zhou J; Chng WJ
    World J Clin Oncol; 2018 Sep; 9(5):90-97. PubMed ID: 30254964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pim kinases modulate resistance to FLT3 tyrosine kinase inhibitors in FLT3-ITD acute myeloid leukemia.
    Green AS; Maciel TT; Hospital MA; Yin C; Mazed F; Townsend EC; Pilorge S; Lambert M; Paubelle E; Jacquel A; Zylbersztejn F; Decroocq J; Poulain L; Sujobert P; Jacque N; Adam K; So JC; Kosmider O; Auberger P; Hermine O; Weinstock DM; Lacombe C; Mayeux P; Vanasse GJ; Leung AY; Moura IC; Bouscary D; Tamburini J
    Sci Adv; 2015 Sep; 1(8):e1500221. PubMed ID: 26601252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biology, clinical relevance, and molecularly targeted therapy in acute leukemia with FLT3 mutation.
    Kiyoi H; Naoe T
    Int J Hematol; 2006 May; 83(4):301-8. PubMed ID: 16757428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FLT3 Inhibitors for Treating Acute Myeloid Leukemia.
    Hassanein M; Almahayni MH; Ahmed SO; Gaballa S; El Fakih R
    Clin Lymphoma Myeloma Leuk; 2016 Oct; 16(10):543-549. PubMed ID: 27450971
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
    Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
    Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The ability of sorafenib to inhibit oncogenic PDGFRbeta and FLT3 mutants and overcome resistance to other small molecule inhibitors.
    Lierman E; Lahortiga I; Van Miegroet H; Mentens N; Marynen P; Cools J
    Haematologica; 2007 Jan; 92(1):27-34. PubMed ID: 17229632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting FLT3 Signaling in Childhood Acute Myeloid Leukemia.
    Sexauer AN; Tasian SK
    Front Pediatr; 2017; 5():248. PubMed ID: 29209600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of resistance to small molecule FLT3 inhibitors: implications for molecularly targeted therapy of acute leukemia.
    Cools J; Mentens N; Furet P; Fabbro D; Clark JJ; Griffin JD; Marynen P; Gilliland DG
    Cancer Res; 2004 Sep; 64(18):6385-9. PubMed ID: 15374944
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.